Q3 Earnings Call 2 1 Completed capital raise: $30M in Equity and $50M in Debt, pulled down $25M ($55M in total) | --- | --- | |------------------------------|-------| | | | | Product Performance Update | | | | | | | | | --- | --- | |--------------------------------------------------------------------------------------|--------------------------------------------------------------------| | | | | • APONVIE | • ZYNRELEF | | – "Above the Waist" starting entry point | – Orthopedic procedure focus | | • Significa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 4242 Campus Point Court, Suite 200 San Diego, CA 92121 (Address of principal executive offices) (Zip Code) Reg ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Jeff Cohen - Executive Director, Assistant General Counsel and Assistant Secretary Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President and Chief Financial Officer Bill Forbes - Executive Vice President and Chief Development Officer Conference Call Participants Serge Belanger - Needham & Company Boris Peaker - TD Cowen Carl Byrnes - Northland Capital Markets Operat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdicti ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Craig Collard - Chief Executive Officer David Szekeres - Executive Vice President & Chief Operating Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Rohit Bhasin - Needham & Company Carl Byrnes - Northland Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2023 Earnings Conference. Before we begin, I would like t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 94-2875566 (State or other jurisdicti ...

Heron Pipeline of 4 Approved Products With $107.7 million in | --- | --- | --- | --- | |------------|------------------------------------------------------------------|------------------------------------|----------------------------------------------------------------| | | ZYNRELEF® (bupivacaine and meloxicam) extended-release solution | sNDA#2 PDUFA Goal October 23, 2023 | US FDA Approved for postsurgical analgesia for up to 72 hours* | | Acute Care | APONVIE™ (aprepitant) injectable emulsion | Launched M ...

Conference Call Participants David Szekeres Barry Quart Because customers have indicated that they would use more ZYNRELEF if it was easier to remove from the vial and the prefilled syringe will take a few years, we have developed an innovative vial access needle, or VAN, which not only reduces the withdrawal time from minutes to around 30 seconds. It also covers the vial to eliminate the need for a non-sterile nurse to be involved withdrawing the drug product. This seamless single person withdrawal tested ...

Forward-Looking Statements Heron Pipeline of 4 Approved Products With $106.7 million in | --- | --- | --- | --- | --- | --- | |---------------|-----------------------------------|-------------|----------|--------------------------------------|----------| | | | PRECLINICAL | CLINICAL | NDA | APPROVED | | | | | | | | | | SUSTOL® (granisetron) | | | US FDA Approved for CINV Prevention* | | | Oncology Care | extended-release injection | | | | | | | CINVANTI® | | | | | | | (aprepitant) injectable emulsion | | | ...